Arovella Therapeutics (ASX:ALA) partners with Imugene (ASX:IMU)

 

Arovella Therapeutics Limited (ASX:ALA) Managing Director and CEO Michael Baker discusses the company’s collaboration with Imugene to combine therapies.

 

Arovella Therapeutics intends to be a world leader as a biotechnology company helping people live longer and healthier lives. The company will develop its existing products and look to acquire additional platforms they believe have an impact on the treatment of cancer and conditions that affect the central nervous system.

About Finance News Network

Established in 2006, the Finance News Network is one of Australia's largest providers of online business and finance news. Our news is distributed across some of Australia’s most prominent investment platforms. The network connects investors with investment opportunities, the latest ASX news, CEO and fund manager interviews and investor webinars. Keep your finger on the pulse and stay abreast of markets. Tune in to FNN. FNN is a subsidary of Sequoia Financial Group

View more articles by Finance News Network →